146 related articles for article (PubMed ID: 31173243)
21. Pinostrobin Inhibits Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) Gene Expression through the Modulation of FoxO3a Protein in HepG2 Cells.
Gao WY; Chen PY; Chen SF; Wu MJ; Chang HY; Yen JH
J Agric Food Chem; 2018 Jun; 66(24):6083-6093. PubMed ID: 29862818
[TBL] [Abstract][Full Text] [Related]
22. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
23. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
[TBL] [Abstract][Full Text] [Related]
24. Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells.
Chen HC; Chen PY; Wu MJ; Tai MH; Yen JH
PLoS One; 2016; 11(9):e0162414. PubMed ID: 27617748
[TBL] [Abstract][Full Text] [Related]
25. Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells.
Kitamura K; Okada Y; Okada K; Kawaguchi Y; Nagaoka S
Mol Nutr Food Res; 2017 Aug; 61(8):. PubMed ID: 28181408
[TBL] [Abstract][Full Text] [Related]
26. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
Theocharidou E; Papademetriou M; Reklou A; Sachinidis A; Boutari C; Giouleme O
Curr Pharm Des; 2018; 24(31):3654-3657. PubMed ID: 30317984
[TBL] [Abstract][Full Text] [Related]
27. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
28. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
29. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
30. Regulation of PCSK9 by nutraceuticals.
Momtazi AA; Banach M; Pirro M; Katsiki N; Sahebkar A
Pharmacol Res; 2017 Jun; 120():157-169. PubMed ID: 28363723
[TBL] [Abstract][Full Text] [Related]
31. Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER.
Li C; Hu Z; Zhang W; Yu J; Yang Y; Xu Z; Luo H; Liu X; Liu Y; Chen C; Cai Y; Xia X; Zhang X; Wang DZ; Wu G; Zeng C
Sci Rep; 2019 May; 9(1):7693. PubMed ID: 31118464
[TBL] [Abstract][Full Text] [Related]
32. PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats.
Amput P; Palee S; Arunsak B; Pratchayasakul W; Kerdphoo S; Jaiwongkam T; Chattipakorn SC; Chattipakorn N
Eur J Pharmacol; 2020 Sep; 883():173347. PubMed ID: 32650007
[TBL] [Abstract][Full Text] [Related]
33. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
34. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
[TBL] [Abstract][Full Text] [Related]
35. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
[TBL] [Abstract][Full Text] [Related]
36. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
[TBL] [Abstract][Full Text] [Related]
37. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
Khera AV; Qamar A; Reilly MP; Dunbar RL; Rader DJ
Am J Cardiol; 2015 Jan; 115(2):178-82. PubMed ID: 25432415
[TBL] [Abstract][Full Text] [Related]
38. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
39. Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells.
Choi HK; Hwang JT; Nam TG; Kim SH; Min DK; Park SW; Chung MY
Food Funct; 2017 Dec; 8(12):4582-4591. PubMed ID: 29130084
[TBL] [Abstract][Full Text] [Related]
40. Role of PCSK9 in lipid metabolism and atherosclerosis.
Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
